Current Radiopharmaceuticals
Title:Editorial (Thematic Issue: Lutetium-177 Labeled Therapeutics: 177Lu-PSMA is Set to Redefine Prostate Cancer Treatment)
Volume: 9 Issue: 1
Author(s): Ambikalmajan M.R. Pillai and Furn F. (Russ) Knapp
Affiliation:
Export Options
About this article
Cite this article as:
Pillai M.R. Ambikalmajan and (Russ) Knapp F. Furn, Editorial (Thematic Issue: Lutetium-177 Labeled Therapeutics: 177Lu-PSMA is Set to Redefine Prostate Cancer Treatment), Current Radiopharmaceuticals 2016; 9 (1) . https://dx.doi.org/10.2174/187447100901151123124826
DOI https://dx.doi.org/10.2174/187447100901151123124826 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Small-Animal Molecular Imaging for Preclinical Cancer Research: μPET and μSPECT
Current Radiopharmaceuticals New Derivatives of GnRH as Potential Anticancer Therapeutic Agents
Current Medicinal Chemistry Therapeutic Targeting of the FKBP52 Co-Chaperone in Steroid Hormone Receptor-Regulated Physiology and Disease
Current Molecular Pharmacology Functional Interplay between RNA-Binding Protein HuR and microRNAs
Current Protein & Peptide Science Targeting Role of Glioma Stem Cells for Glioblastoma Multiforme
Current Medicinal Chemistry Fatty Acid-Binding Proteins at a Glance
Protein & Peptide Letters Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets Cyclotron Production of PET Radiometals in Liquid Targets: Aspects and Prospects
Current Radiopharmaceuticals Estimation of Affinity of HLA-A*0201 Restricted CTL Epitope Based on the SCORE Function
Protein & Peptide Letters Imaging in the Age of Molecular Medicine: Monitoring of Anti-Angiogenic Treatments
Current Pharmaceutical Biotechnology “Virostatics” as a Potential New Class of HIV Drugs
Current Pharmaceutical Design Characterization of a New Allelic Variant of Triosephosphate Isomerase from the LNCaP Human Prostate Cancer Cell Line: Enzyme Inhibition and Spectroscopic Studies
Current Enzyme Inhibition Microwave-Assisted Synthesis of Imido-Substituted 2-Chloro-1,4-naphthoquinone Derivatives and their Cytotoxic Activities on Three Human Prostate Cancer Cell Lines
Letters in Drug Design & Discovery Targeting Oncogenes and Tumor Suppressors genes to Mitigate Chemoresistance
Current Cancer Drug Targets Impact of PLK-1 Silencing on Endothelial Cells and Cancer Cells of Diverse Histological Origin
Current Gene Therapy Intra-uterine Growth Retardation as a Risk Factor of Postnatal Metabolic Disorders
Current Pharmaceutical Biotechnology Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma
Current Cancer Drug Targets Experimental Research on a Novel Iodine-125 Seed Strand Connected Using Magnesium Alloy AZ31
Recent Patents on Anti-Cancer Drug Discovery Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry Simultaneous Modeling of Antimycobacterial Activities and ADMET Profiles: A Chemoinformatic Approach to Medicinal Chemistry
Current Topics in Medicinal Chemistry